Skip to main content

Coherus Oncology, Inc.

CHRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001512762

No open-market purchases or sales by Coherus Oncology, Inc. insiders were filed in the last 90 days; 146 institutions reported holding it in 13F filings for Q2 2026, worth $98.5M in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Coherus Oncology, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of CHRS: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders117112−5
Shares62.0M55.3M−6.67M (−10.8%)
Value$50.0M$40.4M−$9.58M (−19.2%)

New holders (15)

Institutions that held Coherus Oncology, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to CHRS in Q2 2025
InstitutionSharesValue% of portfolio
Panagora Asset Management Inc794,329$580.9K0.00%
Citadel Advisors LLC134,026$98.0K0.00%
Jane Street Group, LLC63,313$46.3K0.00%
HRT Financial LP48,778$35.0K0.00%
International Assets Investment Management, LLC45,714$33.4K0.00%
Squarepoint Ops LLC41,058$30.0K0.00%
Diversified Trust Co28,159$20.6K0.00%
Virtu Financial LLC24,865$18.0K0.00%
Prudential Financial Inc14,980$10.9K0.00%
ADAR1 Capital Management, LLC10,366$7.58K0.00%
Raymond James Financial Inc3,102$2.27K0.00%
Clearstead Advisors, LLC1,780$1.30K0.00%
Essential Partners LLC464$3390.00%
Sound Income Strategies, LLC200$1460.00%
Larson Financial Group LLC79$580.00%

Sold out (20)

Institutions that held Coherus Oncology, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.